Key facts
- This page summarizes Cintia Piccina's Form 4 filing for Allovir, Inc. (KLRS).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 05 Jul 2023, 17:00.
Cintia Piccina - 03 Jul 2023 Form 4 Insider Report for Allovir, Inc. (KLRS)
- Reporting relationship
- Chief Commercial Officer
- Issuer ticker
- KLRS
- Reported as of
- 03 Jul 2023
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 05 Jul 2023, 17:00:20 UTC
- Prior SEC filing
- 21 Jun 2023
- Next SEC filing
- 18 Mar 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Brett Hagen, as Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Cintia Piccina filed Form 4 for Allovir, Inc. (KLRS) on 05 Jul 2023.
Change
- Previous filing in this sequence was filed on 21 Jun 2023.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
ALVR
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +147,000
- Change %
- Price
- $0.000000
- Shares after
- 147,000
- Date
- 03 Jul 2023
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
ALVR
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +273,000
- Change %
- Price
- $0.000000
- Shares after
- 273,000
- Date
- 03 Jul 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 273,000
- Exercise price
- $3.24
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
The shares reported in this transaction represent Restricted Stock Units ("RSUs") issued under the AlloVir, Inc. 2020 Stock Option and Grant Plan (the "Plan"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. 25% of the RSUs shall vest on June 12, 2024, with the remainder vesting in twelve equal quarterly installments thereafter.
Footnote F2
25% of this option shall vest and become exercisable on June 12, 2024, with the remainder vesting in twelve equal quarterly installments thereafter.